BioMarin All Set For Hemophilia Gene Therapy Approval, But Is It Overestimating Demand?
Gearing Up For August Approval
Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.
You may also be interested in...
The company lowered revenue guidance due to COVID-19, but announced a new brand name, Roctavian, for its hemophilia A gene therapy, which it said remains on track for FDA approval later this year.
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.